Cryoport, Inc. (CYRX) AI Stock Analysis

Cryoport, Inc. provides specialized logistics solutions for the life sciences industry across the Americas, Europe, the Middle East, Africa, and the Asia Pacific. Its core offering is Cryoportal, a cloud-based logistics management platform handling temperature-sensitive shipments, order entry, customs compliance, and real-time tracking. The company utilizes CryoPort Express Shippers and the SmartPak Condition Monitoring System to protect and validate biologic materials in transit. Additionally, Cryoport supplies cryogenic freezer systems and vacuum insulated aluminum dewars for specimen cryopreservation and storage, complemented by specimen logistics management and consulting services.

Cryoport generated revenue of $176.2M in FY2025, down 24.5% from $233.3M in FY2024, though its 5-year revenue CAGR from FY2020 to FY2025 stood at 17.5%. Gross margin expanded to 47.1% in FY2025 compared to 42.6% in FY2024. FY2025 net income reached $78.3M with a 44.4% net margin, though diluted EPS was -$0.92, following a net loss of -$99.6M in FY2024. Operating margin was -20.9% in FY2025 and -20.4% over the trailing twelve months. In the latest quarter ended June 30, 2026, quarterly revenue grew 7.7% year-over-year, while trailing twelve-month revenue reached $186.5M with an EPS of -$0.81.

As of June 30, 2026, Cryoport held $396.7M in cash and short-term investments against total debt of $232.0M, resulting in net cash of $164.7M. The current ratio stood at 2.08, and the debt-to-equity ratio was 0.47 based on shareholders' equity of $490.7M and total assets of $756.2M. In FY2025, operating cash flow was -$8.6M and free cash flow was -$28.1M. Capital allocation in FY2025 included $19.5M in capital expenditures, $10.0M in share buybacks, and $8.0M in dividends paid.

CYRX trades at a forward P/E of 79.4x and a price-to-sales multiple of 4.6x, compared to the median of its US-listed Industrials peers of 17.2x forward P/E and 1.5x price-to-sales. Enterprise value stands at $768.0M, equating to an EV-to-revenue multiple of 4.1x. The stock closed at $16.84 on October 16, 2026, up 57.2% over the past year compared to a 16.8% return for the S&P 500 (SPY), but down 76.0% over the past 5 years.

Wall Street analysts hold 7 Strong Buy, 1 Buy, and 1 Hold ratings on Cryoport, with no Sell or Strong Sell ratings. The mean price target of $19.78 implies 17.4% upside from the last close of $16.84. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $195.5M and an EPS of -$0.77. For the next fiscal year, 3 analysts estimate revenue of $215.2M and EPS of -$0.66. Cryoport has beaten EPS estimates in 2 of the last 4 quarters, with its next earnings date scheduled for November 3, 2026.

This page is an AI-written research summary of Cryoport, Inc. (CYRX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: CYRX income statement, CYRX balance sheet, CYRX key metrics, CYRX analyst forecast, CYRX chart. See the CYRX stock overview for the latest quote and news.